Health Care [ 12/12 ] | Biotechnology [ 69/75 ]
NASDAQ | Common Stock
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.
Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.
The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus.
It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH.
The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -0.35 Increased by +82.27% | - |
| May 15, 24 | -0.46 Increased by +77.61% | -0.87 Increased by +46.98% |
| Mar 11, 24 | -0.86 Increased by +68.15% | -1.33 Increased by +35.34% |
| Nov 14, 23 | -1.40 Decreased by -677.78% | -1.27 Decreased by -10.24% |
| Aug 14, 23 | -2.00 Decreased by -952.63% | -1.81 Decreased by -10.50% |
| May 12, 23 | -2.06 Decreased by -930.00% | -3.01 Increased by +31.56% |
| Mar 29, 23 | -2.70 Decreased by -1.13 K% | -2.89 Increased by +6.57% |
| Nov 14, 22 | -0.18 Increased by +5.26% | -0.20 Increased by +10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -8.20 M Increased by +49.50% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.19 M Increased by +71.54% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.88 M Increased by +N/A% | -8.62 M Increased by +58.68% | Decreased by -298.96% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.06 M Increased by +47.47% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -16.23 M Increased by +18.65% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -18.24 M Increased by +8.58% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -20.85 M Decreased by -4.00% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -19.15 M Decreased by -12.59% | Decreased by N/A% Decreased by N/A% |